Tagged as: MAILISHU

Mabwell Announces Approval of Denosumab Biosimilar MAILISHU in China

On March 31, 2023, Mabwell announced that China’s National Medical Products Administration (NMPA) has approved MAILISHU, a denosumab biosimilar, for the treatment of osteoporosis in postmenopausal women at high risk of fracture. MAILISHU was developed by Mabwell’s wholly owned subsidiary, T-Mab. Mabwell stated that MAILISHU is the world’s second approved…

Read More